KURA
Kura Oncology, Inc.
Key Financials
Operating Income
$-303631000
↓ 57.2%
Revenue
$67.5M
↑ 25.2%
Net Income
$-278666000
↓ 60.2%
Total Liabilities
$564.2M
↑ 62.8%
EPS (Diluted)
$-3.18
↓ 57.4%
Total Assets
$738.4M
↓ 2.9%
Shareholders' Equity
$174.1M
↓ 57.9%
Long-term Debt
$9.7M
↑ 1.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| ARS | 4/10/2026 | View on SEC |
| DEFA14A | 4/10/2026 | View on SEC |
| DEF 14A | 4/10/2026 | View on SEC |
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| 4 | 3/25/2026 | View on SEC |
| 4 | 3/20/2026 | View on SEC |
| 10-K | 3/5/2026 | View on SEC |
| 8-K | 3/5/2026 | View on SEC |
| SCHEDULE 13G/A | 2/17/2026 | View on SEC |
| SCHEDULE 13G | 2/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KURA |
| Company Name | Kura Oncology, Inc. |
| CIK | 1422143 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 500-8800 |